Evidence map›Paper›PMID 33604985›Full record

ReviewThe FEBS journal2022

Traptamer screening: a new functional genomics approach to study virus entry and other cellular processes.

Jian Xie, Daniel DiMaio

Abstract readReview
In one paragraph

Review in The FEBS journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jian XieDepartment of Genetics, Yale School of Medicine, New Haven, CT, USA.
Daniel DiMaioDepartment of Genetics, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-2060-5977

Funding

Mechanisms of human papillomavirus entryR35CA242462 · NCI · YALE UNIVERSITY · PI Daniel C. Dimaio · 2020 to 2026
$6.9M
Retrograde TGN/Golgi transport and nuclear targeting of HPV during entryR01AI150897 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Daniel C. Dimaio, Billy Tsai · 2020 to 2026
$3.5M
Role of Retromer-mediated Retrograde Transport in HPV EntryR01AI102876 · NIAID · YALE UNIVERSITY · PI DIMAIO, DANIEL C. · 2013 to 2020
$3.1M
NCI NIH HHS R35 CA242462NIAID NIH HHS R01 AI102876NIAID NIH HHS R01 AI150897
6 · The paper itself

Abstract

Historically, the genetic analysis of mammalian cells entailed the isolation of randomly arising mutant cell lines with altered properties, followed by laborious genetic mapping experiments to identify the mutant gene responsible for the phenotype. In recent years, somatic cell genetics has been revolutionized by functional genomics screens, in which expression of every protein-coding gene is systematically perturbed, and the phenotype of the perturbed cells is determined. We outline here a novel functional genomics screening strategy that differs fundamentally from commonly used approaches. In this strategy, we express libraries of artificial transmembrane proteins named traptamers and select rare cells with the desired phenotype because, by chance, a traptamer specifically perturbs the expression or activity of a target protein. Active traptamers are then recovered from the selected cells and can be used as tools to dissect the biological process under study. We also briefly describe how we have used this new strategy to provide insights into the complex process by which human papillomaviruses enter cells.

Indexed as

GenomicsVirus InternalizationAmino Acid SequenceCell LineCell LineageGene Expression RegulationHumansMass ScreeningMembrane ProteinsProtein TransportMembrane Proteinsartificial proteinsBPV E5 proteingenetic screeningHPVhuman papillomavirusRab7retromertransmembrane proteinstraptamers

Identifiers

PMID33604985
PMCPMC8371075

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.